Protagonist Therapeutics develops peptide and small molecule medicines for inflammatory, blood and metabolic diseases. PTGX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (10 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for PTGX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTGX is in one of them and how their past PTGX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Protagonist Therapeutics
Protagonist Therapeutics is a drug discovery and development company based in Newark, California. It is developing medicines for inflammatory skin conditions, a rare blood disorder called polycythemia vera, and obesity. Its key candidates include Icotyde, a treatment for plaque psoriasis being developed with Johnson & Johnson, and rusfertide, an injectable therapy for polycythemia vera developed with Takeda. These medicines are intended for patients with these conditions, and its partners are large drugmakers.
